Because CML has the propensity to evolve from the CP to the AP and BC, with different responses to targeted therapy such as TK inhibitors, the molecular understanding of the mechanism of resistance in this neoplasia is advancing rapidly. The gene discussed is CP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.